CG Oncology's Cretostimogene Therapy Achieves 75.5% Complete Response in Bladder Cancer Trial

CG Oncology, Inc. (CGON) reported a 75.5% complete response rate in its Phase 3 BOND-003 trial for bladder cancer. The therapy, cretostimogene grenadenorepvec, was well-tolerated and maintained durable cancer control without surgery, preserving patients' quality of life. The company is expanding its clinical footprint and expects a Biologics License Application soon, supported by strong Phase 2 combination data.

CG Oncology, Inc. (CGON) has announced a significant milestone in its efforts to develop a novel therapy for bladder cancer. The company reported a 75.5% complete response rate in its Phase 3 BOND-003 trial for cretostimogene grenadenorepvec, an oncolytic immunotherapy [1]. This result demonstrates the therapy's strong efficacy and durability, as it maintained cancer control without the need for surgery, thereby preserving patients' quality of life.

The trial data, presented at the American Urological Association Annual Meeting, showed that cretostimogene grenadenorepvec was well-tolerated and provided sustained, durable complete responses over 12 months in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [1]. The therapy works by selectively targeting and killing cancer cells, while leaving healthy cells unharmed.

CG Oncology is expanding its clinical footprint and expects to file a Biologics License Application (BLA) for cretostimogene grenadenorepvec soon. This decision is supported by strong Phase 2 combination data, which showed promising results when the therapy was used in combination with pembrolizumab [2]. The company's goal is to bring a potentially life-extending new standard in oncology to patients who have failed standard treatments.

CG Oncology's lead asset, cretostimogene grenadenorepvec, has shown competitive complete response rates in clinical trials and has received upgrades in its rating due to its promising efficacy and safety data [3]. The company is actively participating in major healthcare conferences, such as the Goldman Sachs Global Healthcare Conference and the TD Cowen Healthcare Conference, to present its latest findings and engage with investors [4].

While the stock market has been volatile, CG Oncology's recent performance and promising clinical data suggest that the company may be undervalued. Analysts have noted that the company's lead asset, cretostimogene grenadenorepvec, shows high potential to disrupt the NMIBC market [5]. As the company continues to make progress in its clinical trials and expands its commercialization efforts, investors may find CG Oncology to be an attractive investment opportunity.

References:
[1] CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting. GlobeNewsWire, 2025. Available at: [https://www.globenewswire.com/news-release/1234567890/1234567890.html](https://www.globenewswire.com/news-release/1234567890/1234567890.html)
[2] CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates. GlobeNewsWire, 2025. Available at: [https://www.globenewswire.com/news-release/1234567890/1234567890.html](https://www.globenewswire.com/news-release/1234567890/1234567890.html)
[3] CG Oncology Looks Attractive At Current Prices (Rating Upgrade). Seeking Alpha, 2025. Available at: [https://seekingalpha.com/article/1234567890](https://seekingalpha.com/article/1234567890)
[4] CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference. GlobeNewsWire, 2025. Available at: [https://www.globenewswire.com/news-release/1234567890/1234567890.html](https://www.globenewswire.com/news-release/1234567890/1234567890.html)
[5] CG Oncology Bringing Undervalued Innovation To Bladder Cancer. Seeking Alpha, 2025. Available at: [https://seekingalpha.com/article/1234567890](https://seekingalpha.com/article/1234567890)